Company profile: Alantos
1.1 - Company Overview
Company description
- Provider of chemistry-driven biopharmaceutical discovery and development of small molecule drugs for osteoarthritis, inflammation, and type II diabetes; offerings include tissue remodeling pathways for rheumatoid arthritis and a dipeptidyl peptidase IV inhibitor.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alantos
Embecta
HQ: United States
Website
- Description: Provider of diabetes healthcare products and services, offering insulin syringes in various sizes, including 6mm needles and BD Veo with BD Ultra-Fine markings; BD AutoShield Duo pen needles with dual-end shields; accessories to support injections; and embassador Companion 24/7, a digital platform with educational content, health management tools, and diabetes-friendly recipes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embecta company profile →
Semma Therapeutics
HQ: United States
Website
- Description: Provider of transformative therapies for Type 1 diabetes, leveraging an exclusively licensed breakthrough method from Professor Douglas Melton's lab to generate billions of functional, insulin-producing beta cells in the laboratory.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semma Therapeutics company profile →
Emperra
HQ: Germany
Website
- Description: Provider of GSM- and web-based telemedical solutions for diabetes management, enabling tracking, monitoring and transmission of insulin doses, blood glucose and carbohydrate data. Offers the ESYSTA system with automatic capture of insulin units and blood glucose, plus the ESYSTA Portal and App for authorized healthcare professionals to adjust treatment. Runs the ESYSTA S-T-A-R-T field trial with a smart insulin pen and telemonitoring in statutory health insurance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emperra company profile →
Osler Diagnostics
HQ: United Kingdom
Website
- Description: Provider of portable, low-cost, quick, and easy-to-use lab-quality diagnostics, featuring the Osler Origin 'portable lab' for a wide range of tests across healthcare settings. Offers lab-in-your-hand technology with microfluidic sample preparation and electrochemical biosensing, HemaTap sample addition for simplified cartridges, and a comprehensive test menu.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Osler Diagnostics company profile →
Nova Biomedical
HQ: United States
Website
- Description: Provider of advanced technology blood testing analyzers and diagnostic products using electrochemical and optical measuring techniques, including critical care blood gas analyzers (Stat Profile Prime Plus, Stat Profile pHOx Ultra), BioProfile FLEX2 for automated cell culture testing, Nova Max Pro for creatinine/eGFR kidney screening, Nova Vet ketone/glucose meter, and Lactate Plus for lactate monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nova Biomedical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alantos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alantos
2.2 - Growth funds investing in similar companies to Alantos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alantos
4.2 - Public trading comparable groups for Alantos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →